13F Holdings
中文EN

FENC FENNEC PHARMACEUTICALS INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—

Returns

ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x

Cash quality & payout

Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$44.64M$47.54M$21.25M$1.53M—
Cost of revenue——$1.26M$86,000—
Gross profit——$19.99M$1.45M—
R&D expense$250,000$307,000$56,000$3.53M$4.98M
SG&A expense$28.29M$23.05M$20.59M$17.72M$12.24M
Operating income-$6.28M$2.57M-$12.77M-$22.59M-$17.22M
Interest expense$2.08M$4.07M$3.39M——
Pretax income-$9.63M-$71,000-$16.05M-$10.55M-$9.12M
Income tax$106,000$365,000—$0$0
Net income-$9.74M-$436,000-$16.05M-$23.71M-$17.35M
EPS (basic)-0.34-0.02-0.60-0.90-0.67
EPS (diluted)-0.34-0.02-0.60-0.90-0.67
Weighted avg. shares (diluted)28.58M27.29M26.57M26.27M26.01M
Banking
Net interest income——$441,000$195,000—
Balance sheet
Cash & equivalents$36.79M$26.63M$13.27M$23.77M$21.10M
Current assets$67.04M$44.12M$26.86M$26.73M$22.39M
Total assets$70.55M$44.95M$26.86M$26.94M$22.41M
Current liabilities$10.52M$6.92M$7.55M$4.61M$1.65M
Long-term debt—$19.34M$30.93M$24.90M$5.00M
Total debt—$19.34M$30.93M$24.90M$5.00M
Total liabilities$35.08M$50.82M$38.49M$29.51M$6.64M
Shareholders' equity$35.47M-$5.87M-$11.62M-$2.57M$15.77M
Net debt—-$7.30M$17.66M$1.12M-$16.10M
Shares outstanding34.16M27.53M27.03M26.36M26.01M
Cash flow statement
Operating cash flow-$12.47M$26.98M-$17.14M-$18.06M-$14.22M
Financing cash flow$22.63M-$13.62M$6.64M$20.73M$4.98M
Stock-based compensation$7.03M$5.06M$5.35M$4.09M$3.75M

Free plan shows the latest 5 periods; Pro shows all 28 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.